WELL Health Technologies Valuation

Q: What is the Fair Price of WELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

WELL (CA$4.39) is trading below our estimate of [[fair value]] (CA$29.11)

Is WELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: WELL (CA$4.39) is trading below our estimate of fair value (CA$29.11)

Significantly Below Fair Value: WELL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WELL?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for WELL. This is calculated by dividing WELL's market cap by their current preferred multiple.
What is WELL's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CA$1.10b

WELL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	14.9x
PEG Ratio	-0.1x

Price to Earnings Ratio vs Peers

How does WELL's PE Ratio compare to its peers?

The above table shows the PE ratio for WELL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	64.9x
AND Andlauer Healthcare Group	25.1x	n/a	CA$1.6b
VMD Viemed Healthcare	33x	49.4%	CA$311.8m
NLH Nova Leap Health	152.4x	n/a	CA$26.8m
SIA Sienna Senior Living	49x	n/a	CA$1.4b
WELL WELL Health Technologies	7.4x	-73.9%	CA$1.1b

Price-To-Earnings vs Peers: WELL is good value based on its Price-To-Earnings Ratio (7.4x) compared to the peer average (64.9x).

Price to Earnings Ratio vs Industry

How does WELL's PE Ratio compare vs other companies in the North American Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	63.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	63.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: WELL is good value based on its Price-To-Earnings Ratio (7.4x) compared to the North American Healthcare industry average (24.5x).

Price to Earnings Ratio vs Fair Ratio

What is WELL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WELL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	7.4x
Fair PE Ratio	5.6x

Price-To-Earnings vs Fair Ratio: WELL is expensive based on its Price-To-Earnings Ratio (7.4x) compared to the estimated Fair Price-To-Earnings Ratio (5.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst WELL forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CA$4.39	CA$7.55 +71.9%	19.8%	CA$10.00	CA$5.00	n/a	15
Oct ’25	CA$4.40	CA$7.61 +73.0%	19.6%	CA$10.00	CA$5.00	n/a	15
Sep ’25	CA$4.50	CA$7.61 +69.2%	19.6%	CA$10.00	CA$5.00	n/a	15
Aug ’25	CA$4.70	CA$7.52 +60.0%	21.3%	CA$10.00	CA$4.75	n/a	14
Jul ’25	CA$4.71	CA$7.52 +59.6%	21.3%	CA$10.00	CA$4.75	n/a	14
Jun ’25	CA$3.75	CA$7.45 +98.7%	20.8%	CA$10.00	CA$4.75	n/a	15
May ’25	CA$3.61	CA$7.39 +104.7%	20.5%	CA$10.00	CA$4.75	n/a	16
Apr ’25	CA$3.67	CA$7.45 +103.1%	22.0%	CA$11.00	CA$4.75	n/a	16
Mar ’25	CA$4.19	CA$7.44 +77.6%	22.2%	CA$11.00	CA$4.75	n/a	17
Feb ’25	CA$3.79	CA$7.69 +102.8%	22.5%	CA$11.00	CA$4.75	n/a	16
Jan ’25	CA$3.85	CA$7.87 +104.3%	20.4%	CA$11.00	CA$5.25	n/a	15
Dec ’24	CA$3.90	CA$7.87 +101.7%	20.4%	CA$11.00	CA$5.25	n/a	15
Nov ’24	CA$3.68	CA$8.21 +123.2%	19.9%	CA$12.00	CA$5.50	CA$4.39	14
Oct ’24	CA$4.15	CA$8.21 +97.9%	19.9%	CA$12.00	CA$5.50	CA$4.40	14
Sep ’24	CA$4.76	CA$8.21 +72.6%	19.9%	CA$12.00	CA$5.50	CA$4.50	14
Aug ’24	CA$4.56	CA$8.30 +82.1%	22.7%	CA$13.50	CA$5.50	CA$4.70	14
Jul ’24	CA$4.75	CA$8.20 +72.6%	23.3%	CA$13.50	CA$5.50	CA$4.71	14
Jun ’24	CA$5.11	CA$8.25 +61.4%	22.5%	CA$13.50	CA$5.50	CA$3.75	15
May ’24	CA$5.78	CA$8.00 +38.4%	25.0%	CA$13.50	CA$5.00	CA$3.61	14
Apr ’24	CA$4.86	CA$7.96 +63.8%	26.0%	CA$13.50	CA$5.00	CA$3.67	13
Mar ’24	CA$4.33	CA$7.83 +80.8%	27.0%	CA$13.50	CA$5.00	CA$4.19	13
Feb ’24	CA$3.67	CA$7.70 +109.7%	26.9%	CA$13.50	CA$5.00	CA$3.79	14
Jan ’24	CA$2.84	CA$7.66 +169.7%	27.1%	CA$13.50	CA$5.00	CA$3.85	14
Dec ’23	CA$3.12	CA$7.66 +145.5%	27.1%	CA$13.50	CA$5.00	CA$3.90	14
Nov ’23	CA$3.01	CA$7.96 +164.6%	23.4%	CA$13.50	CA$6.00	CA$3.68	14

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.